Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

Benzinga · 2d ago
Leerink Partners analyst Asthika Goonewardene assumes Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and raises Price Target to $8.